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Abstract:  Among the several rotenoids, amorphigenin is isolated from the leaves of Amopha Fruticosa and it is known that 
has anti-proliferative effects and anti-cnacer effects in many cell types. The main aim of this study was to investigate the effects 
of amorphigenin on osteoclast differentiation in vitro and on LPS treated inflammatory bone loss model in vivo. We show here 
that amorphigenin inhibited RANKL-induced osteoclast differentiation from bone marrow macrophages in a dose dependent 
manner without cellular toxicity. Anti-osteoclastogenic properties of amorphigenin were based on a down-regulation of c-fos 
and NFATc1. Amorphigenin markedly inhibited RANKL-induced p38 and NF-κB pathways, but other pathways were not 
affected. Micro-CT analysis of the femurs showed that amorphigenin protected the LPS-induced bone loss. We concluded that 
amorphigenin can prevent inflammation-induced bone loss. Thus we expect that amorphigenin could be a treatment option for 
bone erosion caused by inflammation.
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osteoclasts and bone formation by osteoblasts can be caused 
by various hormones and cytokines, which often leads to 
bone diseases such as autoimmune arthritis, periodontitis, 
postmenopausal osteoporosis, paget’s disease, and bone 
tumors (Rodan & Martin, 2000; Takayanagi et al., 2000).
The first line treatment that are currently used in treating 
osteoporosis primarily include bisphosphonates (e.g. 
alendronate, risedronate), along with estrogen replacement 
therapy, selective estrogen receptor modulators (SERM), and 
calcitonin for postmenopausal osteoporosis. However, such 
therapies are associated with adverse effects, including breast 
cancer, endometritis, thromboembolism, hypercalcemia, GI 
problems, and hypertension (Lloyd 1998; Rodan & Martin, 
2000; O’Regan & Gradishar, 2001; Body 2002; Watts 2003).
Most of the drugs we use to treat osteoporosis have many 
side effects. Thus, many plant-derived natural products have 
Introduction
Osteoclasts are bone resorbing multinuclear cells origina-
ting from the hematopoietic stem cells. They attach to the 
exterior of the bone and erode the surface with numerous 
enzymes and acids (Teitelbaum 2000; Boyle et al., 2003). The 
main role of osteoclasts is bone remodeling, they constantly 
dissolve and get rid of old or damaged bones making way 
for the osteoblasts make new ones. Decrease in bone mass 
resulting from imbalance between bone resorption by Effect of amorphigenin on osteoclastogenesis
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been used in traditional medicine for the treatment of various 
diseases. Recently, several previous reports have shown that 
several compounds derived from natural products suppress 
osteoclast differentiation and function (Li et al., 2007; Hu et 
al., 2008). Also, we have previously reported that curcumin, 
a compound derived from Curcuma aromatica, Stewartia 
koreana extract, tanshinone IIA derived from Danshen (also 
called Tanshen, the deried roots of Salvia miltiorrhiza) exert 
an inhibitory effect on osteoclast differentiation and bone 
resorption in vitro and in vivo (Bharti et al., 2004; Kwak et 
al., 2006; Park et al., 2007). More recently, we reported that 
rotenone, which is derived from Derris elliptica, significantly 
inhibits osteoclast differentiation, bone resorption, and bone 
erosion (Kwak et al., 2010). Thus, we screened rotenone 
derivate and examined the effect of amorphigenin in 
osteoclast differentiation and bone resorption in vitro and 
in vivo. Amorphigenin (also known as 8’-hydroxyrotenone), 
an aglycone of the rotenoid glycoside amorphin from plants 
of the genus Amorpha, was initially identified as a flavonoids 
isolated from Amorpha fructiosa (Kloutek et al., 1985). 
Up to now little is known about the biological function of 
amorphigenin. 
In this study, we found that amorphigenin suppressed 
osteoclast differentiation of osteoclast precursors, bone 
marrow-derived macrophages (BMMs). The effect of 
amorphigenin may be involved to the inhibition of c-Fos and 
NFATc1 expression in BMMs treated RANKL. Amorphigenin 
considerably inhibits bone erosion in a mouse model of bone 
loss.
Materials and Methods
Reagents and antibodies
Amorphogen, TRAP assay kit, LPS, and anti-actin anti-
body were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Human soluble RANKL and M-CSF were from 
PeproTech EC (London, UK). For cytotoxicity test, XTT assay 
kit was purchased from Roche Diagnostics (Indianapolis, IN, 
USA). Antibodies against c-Fos and NFATc1 were from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies 
against Phospho (p)-p38, p-JNK, p-ERK, p-Akt, Akt, I-κB 
was purchased from Cell signaling Technology (Beverly, MA). 
ICR mice were from Dae Han Biolink Co. Ltd. (Chungbuk, 
Korea).
Osteoclast differentiation
Bone marrow cells (BMCs) were isolated from long bones 
of 5-week-old ICR mouse by flushing with α-minimum 
essential medium (α-MEM; Welgene, Daegu, Korea) 
containing antibiotics (Sigma Aldrich), and further red blood 
cells (RBC) were removed with RBC lysis buffer (Sigma 
Aldrich). The cells were placed on 90-mm culture dishes 
(Corning, NY, USA) and incubated for 1 day in α-MEM 
containing 10% fetal bovine serum (Gibco BRL, Grand Island, 
NY) and antibiotics (Gibco BRL) in the presence of M-CSF 
(10 ng/ml). Nonadherent cells were seeded on 90-mm petri 
dishes and then cultured for 3 days in the presence of M-CSF 
(30 ng/ml). Adherent cells were used as bone marrow-derived 
macrophages (BMMs), namely osteoclast precursors. To 
generate osteoclasts from osteoclast precursors, BMMs were 
further cultured for 4 days in the presence of M-CSF (30 ng/
ml) and RANKL (50 ng/ml) with or without amorphigenin in 
various concentrations. 
RT-PCR
Total RNA was isolated from treated cells by using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
accord  ing to the manufacturer’s protocol. cDNA was 
synthesized from 1 μg of total RNA using oligo dT, 
dNTP, dithiothreitol, RNase inhibitor, 1x PCR buffer, 
and Superscript II reverse transcriptase (Invitrogen). 1 
µl of cDNA was amplified by PCR using Taq polymerase 
(Invitrogen). The following primers were used: c-Fos sense, 
5’-CTGGTGCAGCCCACTCTGGTC-3’; c-Fos antisense, 
5’-CTTTCAGCAGATTGGCAATCTC-3’; NFATc1 sense, 
5’-CAACGCCCTGACCACCGATAG-3’; N FATc1 antisense, 
5’-GGCTGCCTTCCGTCTCATAGT-3’; TRAP sense, 
5’-ACTTCCCAGCCCTTACTAC-3’; TRAP antisense, 
5’-TCAGCACATAGCCCACACCG-3’; GAPD H sense, 
5’-ACCACAGTCCATGCCATCAC-3’; OSCAR sense, 
5’-CTGCTGGTAACGGATCAGCTCCCCAGA-3’; OSCAR 
antisense, 5’-CCAAGGAGCCAGAACCTTCGAAACT-3’; 
GAPDH antisense, 5’-TCCACCACCCTGTTGCTGTA-3’. 
PCR products were electrophoresed on 1% agarose gels and 
visualized under UV after ethidium bromide staining. 
Western blotting
Cells were lysed in lysis buffer containing 50 mM Tris-Cl, 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM sodium 
fluoride, 1 mM sodium vanadate, 1% deoxycholate, and 
protease inhibitors. Proteins were boiled in SDS sample buffer, Anat Cell Biol 43:310~316, 2010 Bong Gyu Kim, et al 312
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resolved by 10% SDS-polyacrylamide gel electrophoresis, and 
transferred to a PVDF membrane (Amersham Biosciences, 
Piscataway, NJ, USA). The membrane was probed with 
antibodies, as indicated, washed extensively, and then 
incubated with secondary antibody conjugated to horseradish 
peroxidase. Bound antibody was detected by using enhanced 
chemiluminescent reagents (ECL plus, GE Healthcare). 
Cytotoxicity assay
BMMs (1×10
4 cells/well) were seeded in triplicate in 
96-well plates in α-MEM and then incubated for 3 days 
with M-CSF (30 ng/ml) in the presence or absence of 
amorphigenin in various concentrations. After 3 days 
incubation, 50 μl of XTT reagents were added to each well 
and incubated for 4 h. Absorbance was measured at 450 nm 
using an ELISA plate reader (Thermomax; Molecular Devices, 
Sunnyvale, CA).
LPS-induced bone erosion
6-week-old ICR mice were intraperitoneally administered 
amorphigenin (10 μg/g of body weight) or PBS 1 day before 
the injection of LPS. Amorphigenin was intraperitoneally 
administered every other day for 8 days. Mice were injected 
intraperitoneally with LPS (5 μg/g of body weight) on days 0 
and 4. The femurs were obtained on the day 8 after the first 
injection of LPS and were fixed in 4% paraformaldehyde for 
1 day. Radiographic images were taken with micro-CT scan 
(NFR-Polaris-S160: Nano Focus Ray, Iksan, Korea). Bone 
volume/tissue volume was calculated by using the VG Studio 
program.
Statistical analysis
All quantitative results are expressed as mean±S.D. from 
at least 3 independent experiments. Differences among 
groups were assessed using the one-factor analysis of variance 
(ANOVA) followed by Duncan’s multiple range test. Values 
of P<0.05 were considered as statistically significant and 
expressed as asterisk.
Results
Amorphigenin inhibits RANKL-mediated osteoclast 
differentiation
Because rotenone significantly inhibits osteoclast differen-
tiation and bone erosion in vitro and in vivo as reported 
previously (Kwak et al., 2010), we examined whether 
amorphigenin, a rotenone derivate, can inhibit osteoclast 
differentiaion. Osteoclasts were differentiated from mouse 
BMMs in the presence of M-CSF (30 ng/ml) plus RANKL 
(50 ng/ml). The BMMs of the control group differentiated 
into mature TRAP-positive multinucleated osteoclasts while 
amorphigenin reduced the formation and numbers of TRAP-
positive multinucleated cells in a dose-dependent manner 
Fig. 1. Amorphigenin inhibits osteoclast differentiation in BMMs. 
(A) BMMs were cultured with M-CSF (30 ng/ml) and RANKL (50 
ng/ml) in the presence of amorphigenin for 4 days. Then the cells 
were fixed in 3.7% formalin, permeabilized in 0.1% Triton X-100, 
and stained for TRAP. Arrows indicate the multinuclear osteoclasts. 
Arrowheads indicate the mononuclear osteoclasts (B) TRAP-positive 
cells were counted as osteoclasts. Askerisks indicate statistical difference 
from the control.Effect of amorphigenin on osteoclastogenesis
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(Fig. 1).
The cytotoxic effect of amorphigenin
Amorphigenin generated a highly negative effect on 
osteoclastogenesis. We measured the effects of amorphigenin 
on BMMs with the XTT assay to exclude the possibility 
that the inhibition was due to cytotoxicity. amorphigenin 
demonstrated no cytotoxic effects at the same doses which 
effectively inhibited osteoclast differentiation (Fig. 2). 
Our results suggest that osteoclast formation inhibited by 
amorphigenin was not due to toxic effects on BMMs.
Amorphigenin inhibits a variety of signals transduced 
by RANKL
RANKL activates a variety of signal transducers that are 
involved in osteoclastogenesis, including p38, JNK, ERK, 
MAPK, Akt, and transcription factor NF-κB (Boyle et al., 
2003), which are recognized as the key factors of osteoclast 
differentiation. Osteoclast precursors were pretreated with 
amorphigenin and stimulated with RANKL at various 
time points. Different signaling pathways were observed. 
Phosphorylation of p38, Akt, and I-κB by RANKL were 
significantly inhibited by amorphigenin, but amorphigenin 
did not affect the phosphorylation of JNK and ERK (Fig. 
3). This raises the possibility that the negative effect of 
amorphigenin is dependent on its inhibitory effect of certain 
signal transduction molecules such as p38 and NF-κB. 
Amorphigenin decreased the RANKL induced mRNA 
and protein levels of c-fos, NFATc1, TRAP, and 
OSCAR
We know from numerous previous reports that c-Fos 
and NFATc1 play a vital role in osteoclast differentiation. 
We examined the potential effects of amorphigenin on the 
expression of c-Fos and NFATc1 in response to RANKL. As 
shown in Fig. 4, amorphigenin inhibited the expression of 
c-Fos, NFATc1 and OSCAR mRNA expression in response 
to RANKL. Therefore, c-Fos and NFATc1 may be targets of 
amorphigenin in the inhibition of osteoclast differentiation 
induced by RANKL.
Amorphigenin suppresses the protein expression of 
c-fos and NFATc1 induced by RANKL
To elucidate the inhibitory effect of amorphigenin in 
mRNA expression, we next examined whether amorphigenin 
inhibits the protein levels of c-Fos and NFATc1 induced by 
RANKL, as shown by RT-PCR results. BMMs were treated 
with RANKL in the presence or absence of amorphigenin. 
Fig. 2. Effect of amorphigenin on cytotoxicity. BMMs were seded onto 
96-well plate. Then the cells were cultured for 3 days with the indicated 
concentration of amorphigenin in the presence of M-CSF (30 ng/
ml). After 3 days, XTT reagents were added to each well. The optical 
density was read at 450 nm in an ELISA plate reader after 4 hours of 
incubation. Cell viability was determined relative to the control.
Fig. 3. Effects of amorphigenin in RANKL signaling. BMMs were 
pretreated with or without amorphigenin and stimulated with RANKL 
(100 ng/ml) for the indicated times. The cells were lysed in lysis buffer. 
Cell lysates were performed by Wesern blotting with the indicated 
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Protein levels of c-Fos and NFATc1 were increased in 
BMMs treated with RANKL, as shown by RT-PCR analysis. 
However, the expression of both c-Fos and NFATc1 protein 
was significantly inhibited by amorphigenin (Fig. 5). These 
results suggest that the inhibitory effect of amorphigenin may 
be involved in the inhibition of c-Fos and NFATc1 induced by 
RANKL.
Effect of amorphigenin on LPS-Induced bone erosion 
in vivo 
Osteoclasts are responsible for bone destruction in 
inflam  matory bone disease, and inhibition of osteoclast 
differentiation by amorphigenin treatment may exert anti-
bone resorptive effect in vivo. Therefore to examine the effect 
of amorphigenin on bone erosion in vivo, an inflammatory 
bone disease model was created by intraperitoneal injection 
of LPS into mice. Oral administration of DW with or without 
amorphigenin was performed. On micro-CT scan, LPS 
injection induced severe trabecular bone loss in the femur. 
On the contrary, scans from mice in the oral amorphigenin-
treated group showed significant reduction of bone loss (Fig. 
6A). Furthermore, loss of bone volume (bone volume/tissue 
volume) induced by LPS was prevented in amorphigenin-
administered mice (Fig. 6B).
Fig. 4. Amorphigenin suppresses RANKL-induced gene expression. 
BMMs were pretreated with or without amorphigenin and then 
stimulated with RANKL (100 ng/ml) for the indicated times. Total 
RNA was isolated from the treated cells. The mRNA expression of 
c-fos, NFATc1, TRAP, OSCAR, and GAPDH was analyzed by RT-
PCR.
Fig. 5. Amorphigenin inhibits RANKL-mediated c-Fos and NFATc1 
expression. BMMs were pretreated with or without amorphigenin and 
stimulated with RANKL (100 ng/ml) for the indicated times. The 
cells were lysed in lysis buffer. c-Fos, NFATc1, or actin proteins were 
detected by Western blotting with an anti-c-fos, and anti-NFATc1, or 
anti-actin-antibody, respectively.
Fig. 6. Suppression of LPS-induced bone loss by amorphigenin. 
Mice were injected intraperitonealy with amorphigenin (10 µg/
g of body weight) on days －1, 1, 3, 5, and 7 days. LPS was injected 
intraperitoneally on days 0 and 4. The mice were killed 8 days after the 
first injection of LPS, and femurs were collected. (A) The femurs were 
imaged with a micro-CT machine. (B) Bone volume/tissue volume 
(BV/TV) was analyzed using the histomorphometric results. Asterisks 
indicate statistical difference between the indicated groups.Effect of amorphigenin on osteoclastogenesis
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Discussion
Bone is restructured at such a high speed that approxi-
mately 10% of the total bone content is replaced every year in 
human adults (Rodan & Martin, 2000). This balance is tightly 
regulated by numerous factors, and the most important 
factor is RANKL. Any tip towards one side of this balance 
will lead to osteoporosis or osteopetrosis (Walsh et al., 2006). 
Most of the bone related metabolic disease has osteoclast as a 
main executor. Either a hyperactive or an inactive osteoclast 
is responsible for osteoporosis, inflammatory bone disease 
such as rheumatoid arthritis and periodontitis, paget disease 
and osteopetrosis (Bartold et al., 2005; Everts et al., 2009). 
Therefore, a compound to increase osteoblast activity and 
inhibit osteoclast activity would show potential as an ideal 
therapeutic for osteoporosis. Here we investigated the effect of 
amorphigenin in osteoclast differentiation that is derived from 
the leaves of Amopha Fruticosa. Amorphigenin considerably 
inhibited RANKL-induced osteoclast differentiation from 
BMMs in a dose-dependent manner without toxicity (Figs. 1 
and 2). 
The genes responsible for the differentiation of osteoclasts 
are expressed in different stages of development. In the early 
stage, PU.1 regulates differentiation of primitive hematopoietic 
cells (Hayashi et al., 1998). M-CSF is responsible for inducing 
RANK in the surface of the hematopoietic stem cells, along 
with Bcl-2 for the regulation of survival and apoptosis (Zhao 
et al., 2007). RANKL, RANK, TRAF6, NF-κB, NFATc1, c-Fos, 
and MITF are the major contributors for the differentiation 
of TRAP-positive mononuclear osteoclasts (Boyle et al., 
2003; Teitelbaum & Ross, 2003; Takayanagi 2005). And the 
key transcription factor is NFATc1, for this is the master 
regulator of osteoclast differentiation (Takayanagi et al., 
2002). NFATc1 transcribes DC-STAMP and Atp6v0d2 for 
cell fusion, cathepsin K, TRAP, OSCAR, MMP9 etc for 
function (Takayanagi 2007; Kim et al., 2008). We also found 
that amorphigenin significantly inhibited expression of c-Fos 
and NFATc1 induced by RANKL, and the mRNA expression 
levels of markers of osteoclast such as TRAP and OSCAR was 
also inhibited by amorphigenin (Figs. 4 and 5). These results 
suggest that the differentiating mechanism of osteoclast 
differentiation influenced by amorphigenin is related to 
decreased expression of c-Fos and NFATc1.
LPS, a potent inducer of inflammation in vivo, induced 
bone erosion, although the mechanism of this effect remains 
unknown (Miyaura et al., 2003). We previously have shown 
that LPS greatly induce bone erosion in vivo (Kwak et al., 
2010). Thus, we examined the effect of amorphigenin in 
LPS-mediated bone erosion. Importantly, LPS-injected mice 
showed a profound decrease in the density of trabeculae in 
the femur. However, amorphigenin significantly protected 
bone erosion induced by LPS (Fig. 6). Our results indicated 
that amorphigenin inhibits osteoclastic bone resorption as 
well as differentiation into osteoclasts in vivo.
The mainline drug that is currently used in the treatment 
of osteoporosis is bisphosphonates. The main function of 
bisphophonates is the binding of the drug to the hydroxy-
apatite of the bone, this can distort the absorption capacity 
of the osteoclasts (Russell et al., 1999). Osteoclasts can also 
take this drug into their system, thus triggering an automated 
cell death system and inducing osteoclast apoptosis. Recent 
reports of bisphosphonates-related osteonecrosis of the jaw 
(Filleul et al., 2010) and other adverse effects can limit the use 
of bisphosphonates. The demand for new drugs other than the 
traditional treatment modalities has constantly been up for 
grabs. Therefore, we assert that amorphigenin could be used 
not only for the treatment of post-menopausal osteoporosis 
and senile osteoporosis but also in numerous other areas such 
as in inflammatory arthritis and infectious conditions of bone 
such as osteomyelitis and chronic periodontitis.
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